Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of rAAV2-RPE65 Gene Therapy (LX101) in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy

NCT06196827 is registered in ClinicalTrials.gov with Innostellar Biotherapeutics Co.,Ltd as lead sponsor.

NCT NCT06196827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06196827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of rAAV2-RPE65 Gene Therapy (LX101) in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 2, 2022
Completion date
December 31, 2027
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

inherited retinal dystrophy associated with rpe65 mutations